|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1995-12-12
|
|
pubmed:abstractText |
The purpose of our cooperative trial was to investigate whether epirubicin (EPI) at 90 mg/m2 in a CHOP-like combination (called CEOP) could increase complete response (CR) and survival rates in non-Hodgkin lymphoma (NHL) patients while maintaining a tolerable degree of toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
318-24
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:7590500-Adult,
pubmed-meshheading:7590500-Aged,
pubmed-meshheading:7590500-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7590500-Combined Modality Therapy,
pubmed-meshheading:7590500-Cyclophosphamide,
pubmed-meshheading:7590500-Disease-Free Survival,
pubmed-meshheading:7590500-Epirubicin,
pubmed-meshheading:7590500-Female,
pubmed-meshheading:7590500-Humans,
pubmed-meshheading:7590500-Life Tables,
pubmed-meshheading:7590500-Lymphoma, Non-Hodgkin,
pubmed-meshheading:7590500-Male,
pubmed-meshheading:7590500-Middle Aged,
pubmed-meshheading:7590500-Prednisone,
pubmed-meshheading:7590500-Remission Induction,
pubmed-meshheading:7590500-Survival Rate,
pubmed-meshheading:7590500-Vincristine
|
|
pubmed:articleTitle |
A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Gruppo Cooperativo Lombardo, Istituto di Scienze Mediche, University of Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
